Functional Imaging Using Diffuse Optical Spectroscopy of Neoadjuvant Chemotherapy Response in Women with Locally Advanced Breast Cancer

被引:95
作者
Soliman, Hany [1 ]
Gunasekara, Anoma
Rycroft, Mary
Zubovits, Judit [2 ]
Dent, Rebecca [3 ]
Spayne, Jacqueline [1 ]
Yaffe, Martin J. [4 ]
Czarnota, Gregory J. [1 ,4 ]
机构
[1] Sunnybrook Hlth Sci Ctr, Dept Radiat Oncol, Toronto, ON M4N 3M5, Canada
[2] Sunnybrook Hlth Sci Ctr, Dept Pathol, Toronto, ON M4N 3M5, Canada
[3] Sunnybrook Hlth Sci Ctr, Dept Med Oncol, Toronto, ON M4N 3M5, Canada
[4] Univ Toronto, Dept Med Biophys, Fac Med, Toronto, ON, Canada
关键词
POSITRON-EMISSION-TOMOGRAPHY; PATHOLOGICAL COMPLETE RESPONSE; INVASIVE LOBULAR CARCINOMA; AXILLARY LYMPH-NODES; INDUCTION CHEMOTHERAPY; RECEPTOR STATUS; PRIMARY TUMOR; MAMMOGRAPHY; MRI; THERAPY;
D O I
10.1158/1078-0432.CCR-09-1510
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Functional imaging with tomographic near-infrared diffuse optical spectroscopy (DOS) can measure tissue concentration of deoxyhemoglobin (Hb), oxyhemoglobin (HbO2), percent water (%water), and scattering power (SP). In this study, we evaluated tumor DOS parameters and described their relationship to clinical and pathologic outcome in patients undergoing neoadjuvant therapy for locally advanced breast cancer. Experimental Design: Ten patients were enrolled and intended to undergo five scans each. Scans were taken up to 3 days before treatment and at 1, 4, and 8 weeks after neoadjuvant treatment before surgery. Changes in volume of interest weighted tissue Hb, HbO2, %water, and SP corresponding to the tumor were compared with clinical and pathologic response. Results: All patients' tumor volumes of interest were significantly different compared with background tissue for all parameters. Five patients had a good pathologic response. Four patients were considered nonresponders. One patient initially did not respond to chemotherapy but, after a change in chemotherapy, had a good response. In the five patients with a good response, the mean drop in Hb, HbO2, %water, and SP from baseline to the 4-week scan was 67.6% (SD = 20.8), 58.9% (SD = 20.3), 51.2% (SD = 28.3), and 52.6% (SD = 26.4), respectively. In contrast, the four nonresponders had a mean drop of 17.7% (SD = 9.8), 18.0% (SD = 20.8), 15.4% (SD = 11.7), and 12.6% (SD = 10.2) for Hb, HbO2, %water, and SP, respectively. Conclusions: Responders and nonresponders were significantly different for all functional parameters at the 4-week scan, except for %water, which approached significance. Thus, DOS could be used as an early detector of tumor response. Clin Cancer Res; 16(9); 2605-14. (C) 2010 AACR.
引用
收藏
页码:2605 / 2614
页数:10
相关论文
共 44 条
  • [31] Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies
    Padhani, AR
    Husband, JE
    [J]. CLINICAL RADIOLOGY, 2001, 56 (08) : 607 - 620
  • [32] Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer
    Ring, AE
    Smith, IE
    Ashley, S
    Fulford, LG
    Lakhani, SR
    [J]. BRITISH JOURNAL OF CANCER, 2004, 91 (12) : 2012 - 2017
  • [33] SATALOFF DM, 1995, J AM COLL SURGEONS, V180, P297
  • [34] ADVANCED PRIMARY BREAST-CANCER - ASSESSMENT AT MAMMOGRAPHY OF RESPONSE TO INDUCTION CHEMOTHERAPY
    SEGEL, MC
    PAULUS, DD
    HORTOBAGYI, GN
    [J]. RADIOLOGY, 1988, 169 (01) : 49 - 54
  • [35] Combined diffuse optical spectroscopy and contrast-enhanced magnetic resonance imaging for monitoring breast cancer neoadjuvant chemotherapy: a case study
    Shah, N
    Gibbs, J
    Wolverton, D
    Cerussi, A
    Hylton, N
    Tromberg, BJ
    [J]. JOURNAL OF BIOMEDICAL OPTICS, 2005, 10 (05)
  • [36] Revision of the American Joint Committee on Cancer staging system for breast cancer
    Singletary, SE
    Allred, C
    Ashley, P
    Bassett, LW
    Berry, D
    Bland, KI
    Borgen, PI
    Clark, CG
    Edge, SB
    Hayes, DF
    Hughes, LL
    Hutter, RVP
    Morrow, M
    Page, DL
    Recht, A
    Theriault, RL
    Thor, A
    Weaver, DL
    Wieand, HS
    Greene, FL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) : 3628 - 3636
  • [37] Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide plus filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK multicenter study
    Therasse, P
    Mauriac, L
    Welnicka-Jaskiewicz, M
    Bruning, P
    Cufer, T
    Bonnefoi, H
    Tomiak, E
    Pritchard, KI
    Hamilton, A
    Piccart, MJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (05) : 843 - 850
  • [38] Non-invasive in vivo characterization of breast tumors using photon migration spectroscopy
    Tromberg, BJ
    Shah, N
    Lanning, R
    Cerussi, A
    Espinoza, J
    Pham, T
    Svaasand, L
    Butler, J
    [J]. NEOPLASIA, 2000, 2 (1-2): : 26 - 40
  • [39] Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas:: a retrospective study on 860 patients from one institution
    Tubiana-Hulin, M.
    Stevens, D.
    Lasry, S.
    Guinebretiere, J. M.
    Bouita, L.
    Cohen-Solal, C.
    Cherel, P.
    Rouesse, J.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 (08) : 1228 - 1233
  • [40] Primary breast cancer: Mammographic changes after neoadjuvant chemotherapy, with pathologic correlation
    Vinnicombe, SJ
    MacVicar, AD
    Guy, RL
    Sloane, JP
    Powles, TJ
    Knee, G
    Husband, JE
    [J]. RADIOLOGY, 1996, 198 (02) : 333 - 340